Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Challenge Model Optimization
NCT02088892Completed
- Sponsor
- University of Oxford
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of bacillus calmette-guerin substrain danish 1331 live antigen and TICE-strain BCG in Tuberculosis (TB) (5 arms), sponsored by University of Oxford. Primary endpoint: Quantity of BCG at challenge site at Day 14. Started Mar 2014; status: completed.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigenTICE-strain BCG
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02088892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088892.